CHIME responds to MU announcement

CHIME President and CEO Russell Branzell has issued a response to the news from Centers for Medicare & Medicaid Services Acting Administrator Andy Slavitt that the Meaningful Use (MU) program will come to an end this year.

"MU has had a profound impact on the adoption of health information technology and furthering the digitization of the healthcare delivery system. CHIME members have long supported the underlying goals of the program and the industry has made significant progress in implementing IT systems to improve patient care, reduce costs and create a more efficient delivery system.

"At the same time, CHIME has been at the forefront of advocating for refinements to the program to ensure that hospitals and physicians can meet program requirements. We continue to call upon federal regulators to, among other things, better align clinical quality measures and adopt enforceable standards. We also believe that we need a laser-like focus on interoperability to improve health information exchange across the continuum of care. Central to that is finding a safe, accurate and private methodology for patient identification. Interoperable systems, a bigger focus on outcomes and less prescriptive use of how technology is used will better position providers for success in new payment and delivery models of care and ultimately benefit patients care."

Branzell also called for maintaining the momentum in digitizing healthcare. "Robust IT systems are a cornerstone for achieving the Triple Aim--better population health, an improved patient experience and lower costs."

The Medicare Access and CHIP Reauthorization Act of 2015 and other reform efforts to shift to value-based payment will lead to greater alignment between physicians and hospitals, he added. "CHIME believes that it is essential that we create more synergy between Meaningful Use requirements for hospitals and physicians if we are going to fully realize the potential that health IT has in promoting better patient care across the continuum."

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.